A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

[1]  D. Pfister,et al.  Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Chih-Hsin Yang,et al.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Tishler,et al.  Efficacy and toxicity of reirradiation using intensity‐modulated radiotherapy for recurrent or second primary head and neck cancer , 2010, Cancer.

[4]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[5]  L. Paz-Ares,et al.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  E. Baudin,et al.  Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). , 2010 .

[7]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Dancey,et al.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. , 2009, The Lancet. Oncology.

[9]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[10]  C. Langer.  Targeted therapy in head and neck cancer , 2008, Cancer.

[11]  R. Weichselbaum,et al.  Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Herbst,et al.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[14]  T. Reichert,et al.  Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[15]  A. Ryan,et al.  ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. , 2005, Cancer research.

[16]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[17]  J. Ioannidis,et al.  Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2005, Clinical Cancer Research.

[18]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[19]  M. Baur,et al.  Docetaxel/cisplatin as first‐line chemotherapy in patients with head and neck carcinoma , 2002, Cancer.

[20]  F. Khuri,et al.  Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Specht,et al.  Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Janinis,et al.  Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. , 2000, American journal of clinical oncology.

[23]  M. Forni,et al.  A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck , 1999, British Journal of Cancer.

[24]  M. Posner,et al.  Docetaxel in head and neck cancer: a review. , 1998, American journal of clinical oncology.

[25]  P. Busse,et al.  Docetaxel: an active drug for squamous cell carcinoma of the head and neck. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Piccart,et al.  Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck , 1994 .

[27]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  Y. Humblet,et al.  An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.